ReviewCancers2021
Gastrointestinal Manifestations in Systemic Mastocytosis: The Need of a Multidisciplinary Approach.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 5 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 5: Epigenetic Regulation of PD-L1.International journal of molecular sciences · 2021Pooled it
- What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment.International journal of molecular sciences · 2021Pooled it
- Pooled it
- What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models).International journal of molecular sciences · 2021Pooled it
- Pooled it
- Gallbladder Involvement in Aggressive Systemic Mastocytosis.Turkish journal of haematology : official journal of Turkish Society of Haematology · 2026Article
- Symptom patterns before and after indolent systemic mastocytosis: A matched cohort analysis.The journal of allergy and clinical immunology. Global · 2026Article
- Eosinophilic and mastocytic gastrointestinal diseases: current knowledge and controversy in histopathologic diagnosis.Translational gastroenterology and hepatology · 2026Review
- Evidence for dysbiosis in the gut microbiome of patients with systemic mastocytosis.The journal of allergy and clinical immunology. Global · 2026Article
- Article
- Unmasking mast cell infiltrates: augmented reality and AI in GI endoscopy for systemic mastocytosis.Annals of medicine and surgery (2012) · 2025Article
- Aggressive systemic mastocytosis: unraveling the mystery behind chronic diarrhea.Clinical endoscopy · 2025Article
- Unmasking systemic mastocytosis: a case of gastrointestinal involvement misdiagnosed as achalasia.Journal of surgical case reports · 2025Article
- Systemic mastocytosis: current status and challenges in 2024.Blood advances · 2025Review
- Treatment refractory mast cell leukemia with dominant gastrointestinal manifestation and concomitant skin symptoms: A case report.World journal of clinical cases · 2024Article
- Asymptomatic Systemic Mastocytosis Uncovered During Routine Colonoscopy: A Case Report.Cureus · 2024Article
- Diarrhea-predominant irritable bowel syndrome as a masquerade for systemic mastocytosis: review article and illustrating case report.Archives of medical science : AMS · 2024Article
- Case Report: Multidisciplinary management of a patient with indolent systemic mastocytosis and refractory symptoms.Frontiers in allergy · 2024Article
- Aggressive systemic mastocytosis with multiple organ involvement: a case report.Oxford medical case reports · 2023Article
- Small bowel obstruction: a rare presentation of systemic mastocytosis.BMJ case reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mastocytosis represents a heterogeneous group of neoplastic mast cell disorders. The basic classification into a skin-limited disease and a systemic form with multi-organ involvement remains valid. Systemic mastocytosis is a disease often hard to diagnose, characterized by different symptoms originating from either the release of mast cell mediators or organ damage due to mast cell infiltration. Gastrointestinal symptoms represent one of the major causes of morbidity, being present in 60-80% of patients. A high index of suspicion by clinicians and pathologists is required to reach the diagnosis. Gastrointestinal mastocytosis can be a challenging diagnosis, as symptoms simulate other more common gastrointestinal diseases. The endoscopic appearance is generally unremarkable or nonspecific and gastrointestinal mast cell infiltration can be focal and subtle, requiring an adequate sampling with multiple biopsies by the endoscopists. Special stains, such as CD117, tryptase, and CD25, should be performed in order not to miss the gastrointestinal mast cell infiltrate. A proper patient's workup requires a multidisciplinary approach including gastroenterologists, endoscopists, hematologists, oncologists, and pathologists. The aim of this review is to analyze the clinicopathological features of gastrointestinal involvement in systemic mastocytosis, focusing on the relevance of a multidisciplinary approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.